Should I buy or sell Sun Pharma Advanced Research Com?

The average broker rating on Sun Pharma Advanced Research Com is Strong Buy. The breakup of analyst rating is given below - 1 analysts have given a strong sell rating 1 analysts have given a sell rating 1 analysts have given a hold rating 1 analysts have given a buy rating 2 analysts have given a strong buy rating

Is Sun Pharma Advanced Research Com a good stock to invest in?

Sun Pharma Advanced Research Com can be analyzed on the following key metrics - TTM P/E: - Sector P/E: 26.01 Dividend Yield: 0.00 D/E ratio: 0.03

Sun Pharma Advanced Research Com

Sector: Business Services

Powered by

188.5 -1.5 (-0.79%)Updated : Fri 9 Jun, 2023 | 04:28:50

Price Range

Today’s Low188.4

Today’s High190.75

52 Week Low160.5

52 Week High265.75

Key Metrics

Market Cap (In Cr) 6167.53
Beta 1.39
Div. Yield (%) 0.00
P/B 12.03
TTM P/E -
Peg Ratio -
Sector P/E 26.01
D/E 0.03
Open Price 190.75
Prev Close 190.00

View All Metrics

Sun Pharma Advanced Research Com Analysis

Price Analysis

1 Week
0.66%
3 Month
0.03%
6 Month
-21.08%
YTD
-8.89%
1 Year
-10.77%

Risk Meter

44%Balanced risk
44%Balanced risk
44%Balanced risk
44%Balanced risk
44%Balanced risk

Recos

Strong Sell
Sell
Hold
Buy
Strong Buy

Analysts' Views

Ratings
Current
1 W Ago
1 M Ago
3 M Ago

Strong Buy
1
1
0
0

Buy
0
0
0
0

Hold
0
0
0
0

Sell
0
0
0
0

Strong Sell
0
0
0
0

Total
1
1
0
0

Sun Pharma Advanced Research Com Financials

INCOME
BALANCE SHEET
Cashflow

Annual

Quarterly

Period	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Total Revenue	238.78	137.25	252.96	76.81
Selling/ General/ Admin Expenses Total	388.41	290.89	347.56	323.00
Depreciation/ Amortization	11.77	10.16	10.92	9.48
Other Operating Expenses Total	42.32	1.57	3.48	2.27
Total Operating Expense	464.61	333.32	398.66	391.77
Operating Income	-225.83	-196.07	-145.70	-314.95
Net Income Before Taxes	-222.58	-203.40	-151.14	-312.40
Net Income	-222.58	-203.40	-151.14	-312.40
Diluted Normalized EPS	-7.82	-7.92	-5.78	-11.92

View detailed financials

Forecast

Income Sheet (In Cr)Net Income Vs Revenue

Returns Metrics (In Cr)ROA Vs ROE

Sun Pharma Advanced Research Com Technical

Simple Moving Average

5 Day 190.18
10 Day 187.00
20 Day 189.76

50 Day 189.15
100 Day 191.04
300 Day 210.97

Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Allcargo Logistics
292.7
-1.3
-0.44
385.11
194.17
7191.64

Quess Corp
423.95
-5.45
-1.27
704.35
337.45
6284.19

Sun Pharma Advanced Research Com
188.5
-1.5
-0.79
265.75
160.5
6117.23

ICRA
4926.2
24.7
0.5
5455.55
3663.65
4738.65

Brightcom Group
23.53
0.89
3.93
57.7
9.27
4749.58

Sun Pharma Advanced Research Com Shareholding

Shareholding Pattern

Shareholding Trend

0

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meetings
AGM
Dividends
Bonus
Split
Rights

Meeting Date	Purpose
22-May-23	Audited Results & Others
13-Feb-23	Quarterly Results
07-Nov-22	Quarterly Results
08-Aug-22	Quarterly Results & Others
17-May-22	Audited Results
04-Feb-22	Quarterly Results
01-Nov-21	Quarterly Results
01-Sep-21	Others
26-Jul-21	Quarterly Results
17-May-21	Audited Results

View All

Company Profile

ABOUT Sun Pharma Advanced Research Com

Industry Business Services
ISIN INE232I01014
BSE Code 532872
NSE Code SPARC

Sun Pharma Advanced Research Company Limited is an India-based clinical-stage bio pharmaceutical company. The Company is engaged in the business of research and development (R&D) of pharmaceutical products to meet unmet medical needs in the areas of oncology, neurodegeneration and immunology. It develops new chemical entities (NCE), new biological entities (NDDS) and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its NDDS includes Wrap Matrix technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology, which is useful to develop controlled-release tablets. The Company has developed Elepsia XR, using Wrap Matrix technology. Lipexelle technology for ophthalmic formulations. It has developed Xelpros, a BAK-free latanoprost eye drops developed using Lipexelle technology. Xelpros is commercialized by the Company’s partner in the United States. It developed PDP-716 eye drops for the treatment of glaucoma based on its TearAct technology.

MANAGEMENT

Anilkumar Raghavan Chief Executive Officer
Chetan Rajpara Chief Financial Officer
Dinesh Lahoti Chief Compliance Officer, Company Secretary

Sun Pharma Advanced Research Com SUMMARY

Sun Pharma Advanced Research Com is trading -0.79% lower at Rs 188.50 as compared to its last closing price. Sun Pharma Advanced Research Com has been trading in the price range of 190.75 & 188.40. Sun Pharma Advanced Research Com has given -8.89% in this year & 0.66% in the last 5 days.

There are 1 analysts who have initiated coverage on Sun Pharma Advanced Research Com. There are 1 analysts who have given it a strong buy rating & 0 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.

The company posted a net profit of -81.99 Crores in its last quarter.

Listed peers of Sun Pharma Advanced Research Com include Allcargo Logistics (-0.44%), Quess Corp (-1.27%), Sun Pharma Advanced Research Com (-0.79%) etc.

FAQs about Sun Pharma Advanced Research Com

Sun Pharma Advanced Research Com is trading at 188.50 as on Fri Jun 09 2023 04:28:50. This is -0.79% lower as compared to its previous closing price of 190.00.

The market capitalization of Sun Pharma Advanced Research Com is 6117.23 Cr as on Fri Jun 09 2023 04:28:50.

The average broker rating on Sun Pharma Advanced Research Com is Strong Buy. The breakup of analyst rating is given below -

1 analysts have given a strong buy rating
0 analysts have given a buy rating
0 analysts have given a hold rating
0 analysts have given a sell rating
0 analysts have given a strong sell rating

The 52 wk high for Sun Pharma Advanced Research Com is 265.75 whereas the 52 wk low is 160.50

Sun Pharma Advanced Research Com can be analyzed on the following key metrics -

TTM P/E: -
Sector P/E: 26.01
Dividend Yield: 0.00%
D/E ratio: 0.03

Sun Pharma Advanced Research Com reported a net profit of -222.58 Cr in 2023.

Sun Pharma Advanced Research Com Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Trending Stocks

Trending Mutual Funds

Sun Pharma Advanced Research Com